Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Morphine sulfate pentahydrate 20mg
Mundipharma New Zealand Ltd
Morphine sulfate pentahydrate 20 mg
20 mg
Film coated tablet
Active: Morphine sulfate pentahydrate 20mg Excipient: Hypromellose Lactose Macrogol 400 Magnesium stearate Opaspray pink M-1-5503 Povidone Pregelatinised maize starch Purified talc Purified water
Blister pack, 10, 10 tablets
Class B1 Controlled Drug
Class B1 Controlled Drug
Macfarlan Smith Ltd
SEVREDOL tablets are indicated for the relief of both acute and chronic severe pain in adults and children aged three years and above.
Package - Contents - Shelf Life: Blister pack, 10 - 10 tablets - 36 months from date of manufacture stored at or below 30°C - Bottle, plastic, 10 - 10 tablets - 36 months from date of manufacture stored at or below 30°C
1993-06-15
NEW ZEALAND DATA SHEET Sevredol tablets Mar 2024 Page 1 of 17 SEVREDOL® TABLETS Morphine sulphate 1 PRODUCT NAME SEVREDOL ® 10 mg and 20 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains morphine sulphate 10 mg or 20 mg Excipient with known affect: Lactose, anhydrous For full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM SEVREDOL tablets are capsule shaped, biconvex, scored, film-coated tablets approximately 12 mm in length with the strength on one side and "IR" on the other side of the score line. The colours of the tablets are as follows: 10 mg blue and 20 mg pink. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS SEVREDOL tablets are indicated for the relief of both acute and chronic severe pain in adults and children aged three years and above. 4.2 DOSE AND METHOD OF ADMINISTRATION DOSE ADULTS AND CHILDREN OVER 12 YEARS: SEVREDOL tablets should be given every four hours. The dosage is dependent upon the nature and severity of the pain, the patient's condition and their previous history of analgesic therapy. The correct dosage per individual patient is that which controls the pain and is well tolerated. A patient initially presenting with severe and intractable pain will normally be started on SEVREDOL 10 mg every 4 hours. This dose should be increased every 4 hours until the desired relief is achieved. SWITCHING FROM SEVREDOL TO LONG-ACTING MORPHINE: Add the amount of morphine needed to achieve pain relief over a 24-hour period. Divide this total in half, rounding up to nearest tablet strength and administer the long acting morphine preparation as a twice daily dose. The first dose of the long acting morphine preparation should be given as a replacement of the last dose of SEVREDOL tablets. Any recurrence of pain will require an increase in the dose but not the frequency of the long acting morphine preparation. Breakthrough pain should be treated with immediate-release morphine, such as SEVREDOL tablets, as rescue dose and not with long-acting formulations. There is no Read the complete document